GO:0030628 pre-mRNA 3'-splice site binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0030628 (pre-mRNA 3'-splice site binding) is a molecular function describing the selective binding of proteins or ribonucleoprotein complexes to the 3' splice site sequence of pre-mRNA.
• The 3' splice site is recognized by the U2AF heterodimer (U2AF1/U2AF2) and associated factors such as FUBP1, which facilitate spliceosome assembly and intron definition.
• Dynamic cycling of U2AF between the 3' splice site and downstream sequences defines two phases of cotranscriptional splicing, linking transcription and splicing.
• Mutations in the 3' splice site or its binding factors cause human disease, including Stargardt disease (ABCA4), TDP-43 proteinopathies (STMN2), and cancers driven by U2AF1 mutations.
• RNA modifications such as pseudouridylation can alter pre-mRNA structure and 3' splice site recognition, expanding the regulatory layer of splicing.
• CRISPR-based knockout, point-mutation, and knock-in models enable functional dissection of 3' splice site binding factors and their disease relevance.
Description
pre-mRNA 3'-splice site binding (GO:0030628) is a molecular function that defines the specific interaction between trans-acting factors and the 3' splice site sequence of precursor messenger RNA (pre-mRNA). This binding event is a critical step in spliceosome assembly, as it helps define the intron-exon boundary and positions the catalytic machinery for the second transesterification reaction of splicing. The 3' splice site typically comprises a polypyrimidine tract followed by an AG dinucleotide, and its recognition is mediated by proteins such as the U2AF heterodimer (U2AF1 and U2AF2) and auxiliary factors like FUBP1. Researchers study GO:0030628 because defects in 3' splice site recognition are directly linked to human disease. For example, mutations that create or destroy 3' splice sites cause aberrant splicing in Stargardt disease and other genetic disorders. In cancer, recurrent mutations in U2AF1 alter 3' splice site preference and drive oncogenic splicing programs. In neurodegeneration, loss of TDP-43 leads to cryptic 3' splice site usage in STMN2, contributing to axonal degeneration. Understanding the molecular details of 3' splice site binding is therefore essential for interpreting disease variants and for developing RNA-targeted therapeutics. This article integrates the QuickGO definition of GO:0030628 with published literature to provide a research-grade overview of its mechanism, key genes, disease connections, and experimental models. It is intended for molecular biologists, geneticists, and therapeutic developers who need a concise yet authoritative resource on pre-mRNA 3' splice site binding.
pre-mRNA 3'-splice site binding At A Glance
| GO ID | GO:0030628 |
|---|---|
| GO term | pre-mRNA 3'-splice site binding |
| Ontology | molecular_function |
| Synonym | pre-mRNA 3' splice site binding |
| Definition | Binding to a pre-mRNA 3' splice site sequence. |
| Major function | Recognition of the 3' splice site by splicing factors to initiate spliceosome assembly and intron removal. |
| Key factors | U2AF1, U2AF2, FUBP1, and other spliceosomal proteins. |
| Disease relevance | Mutations in 3' splice sites or binding factors cause Stargardt disease, TDP-43 proteinopathies, and cancer. |
| Research methods | CRISPR knockout/knock-in, minigene splicing assays, RNA-seq, CLIP-seq. |
What Is GO:0030628?
pre-mRNA 3'-splice site binding (GO:0030628) is the molecular function of selectively and non-covalently interacting with a specific sequence element at the 3' end of an intron in a pre-mRNA molecule. This binding event is a prerequisite for the assembly of the spliceosome at the correct intron-exon boundary and for the subsequent catalytic steps of splicing.
Why Is pre-mRNA 3'-splice site binding Important in Cell Biology?
pre-mRNA 3'-splice site binding is essential for accurate intron removal and for the fidelity of gene expression. Because the 3' splice site is a hotspot for disease-causing mutations, understanding how it is recognized provides a mechanistic basis for interpreting genetic variants and for designing splice-switching therapies. Moreover, dynamic regulation of 3' splice site binding allows cells to respond to transcriptional and signaling cues, and its dysregulation is increasingly implicated in cancer and neurodegeneration.
• Defines intron-exon boundaries and ensures correct splicing of >90% of human genes.
• Mutations in 3' splice sites are a common cause of genetic disease, including Stargardt disease.
• U2AF1 mutations alter 3' splice site recognition and are recurrent in myeloid malignancies.
• Loss of TDP-43 causes cryptic 3' splice site usage in STMN2, linking splicing to neurodegeneration.
• Dynamic U2AF cycling couples transcription with splicing and affects co-transcriptional processing.
• RNA modifications such as pseudouridine can modulate 3' splice site recognition.
• FUBP1 facilitates 3' splice site recognition for long introns, expanding the known factor repertoire.
• AI-assisted tools are being developed to predict the impact of variants on 3' splice site binding.
• CRISPR models enable functional validation of 3' splice site variants and binding factors.
• Therapeutic strategies targeting 3' splice site recognition are emerging for splicing-related diseases.
What Happens During pre-mRNA 3'-splice site binding?
Recognition of the 3' splice site by U2AF
In simple terms: The cell uses a protein complex called U2AF to find the correct end of the intron.
The 3' splice site is initially recognized by the U2AF heterodimer, composed of U2AF1 (U2AF35) and U2AF2 (U2AF65). U2AF2 binds the polypyrimidine tract upstream of the AG dinucleotide, while U2AF1 contacts the AG dinucleotide itself. This binding event is one of the earliest steps in spliceosome assembly and helps recruit the U2 snRNP to the branch point. Dynamic cycling of U2AF between the 3' splice site and downstream sequences defines two phases of cotranscriptional splicing, ensuring that splicing occurs efficiently as the pre-mRNA emerges from RNA polymerase II.
Role of auxiliary factors such as FUBP1
In simple terms: Other proteins help U2AF find the 3' splice site, especially in very long introns.
FUBP1 is a general splicing factor that facilitates 3' splice site recognition and splicing of long introns. It binds to intronic sequences and promotes the recruitment of U2AF to weak polypyrimidine tracts, thereby enhancing splicing efficiency. This auxiliary function is particularly important for genes with long introns, where the distance between the branch point and the 3' splice site is large. FUBP1 thus expands the repertoire of factors that contribute to GO:0030628 and highlights the complexity of 3' splice site recognition.
Coupling with transcription and RNA modifications
In simple terms: Splicing happens while the RNA is still being made, and chemical marks on the RNA can affect it.
pre-mRNA 3' splice site binding is tightly coupled to transcription. U2AF cycling and cotranscriptional splicing ensure that introns are removed as soon as they are synthesized. RNA modifications, such as pseudouridylation by pseudouridine synthases, can alter pre-mRNA structure and affect pre-mRNA processing, including 3' splice site recognition. These findings indicate that GO:0030628 is not a static event but is dynamically regulated by both transcription and the epitranscriptome.
Consequences of defective 3' splice site binding
In simple terms: If the 3' splice site is not recognized properly, the RNA is cut incorrectly, leading to faulty proteins.
Defects in 3' splice site binding lead to exon skipping, intron retention, or activation of cryptic splice sites. In Stargardt disease, noncanonical splice site variants in ABCA4 alter 3' splice site recognition and cause retinal degeneration. In TDP-43 proteinopathies, loss of TDP-43 leads to cryptic splice-polyadenylation of STMN2, which can be corrected by antisense oligonucleotides. These examples illustrate how perturbations in GO:0030628 directly impact human health.
Key Genes Involved in GO:0030628 pre-mRNA 3'-splice site binding
The following genes encode proteins that directly or indirectly participate in pre-mRNA 3'-splice site binding (GO:0030628) or are model targets for studying this function.
| Gene | Major Role | Research Relevance |
|---|---|---|
| U2AF1 | Binds AG dinucleotide at 3' splice site | Mutations in cancer alter 3' splice site selection |
| U2AF2 | Binds polypyrimidine tract | Core factor for 3' splice site recognition |
| FUBP1 | Facilitates 3' splice site recognition for long introns | Auxiliary splicing factor |
| STMN2 | Neuronal gene with cryptic 3' splice site | TDP-43 pathology model |
| ABCA4 | Retinal transporter with noncanonical splice sites | Stargardt disease splicing variants |
| TDP-43 | RNA-binding protein regulating splicing | Neurodegeneration and cryptic splicing |
| SF1 | Binds branch point and assists 3' splice site recognition | Spliceosome assembly |
| U2AF35 | Alternative name for U2AF1 | Cancer-associated mutations |
| U2AF65 | Alternative name for U2AF2 | Polypyrimidine tract binding |
| PTBP1 | Polypyrimidine tract binding protein | Modulates 3' splice site selection |
| hnRNP A1 | Competes with U2AF for 3' splice site | Splicing regulation |
| SRSF1 | SR protein enhancing 3' splice site recognition | Splicing enhancer |
| SRSF2 | SR protein involved in exon definition | Cancer-associated mutations |
| PRPF8 | Core spliceosome component | Catalysis after 3' splice site binding |
| SNRPB | U1 snRNP component | Spliceosome assembly |
| RBM39 | Splicing factor associated with U2AF | Cancer therapy target |
| DDX46 | RNA helicase in spliceosome | Spliceosome dynamics |
How Is pre-mRNA 3'-splice site binding Regulated?
pre-mRNA 3' splice site binding is regulated at multiple levels. Transcription elongation rates influence the timing of 3' splice site recognition and U2AF cycling. RNA modifications, such as pseudouridylation, can alter pre-mRNA secondary structure and accessibility of the 3' splice site. Additionally, the abundance and post-translational modification of splicing factors like U2AF1 and FUBP1 modulate their binding affinity and specificity. Signaling pathways that control splicing factor expression, such as the mTOR pathway, can indirectly affect 3' splice site recognition, although direct evidence in the context of GO:0030628 remains an active area of research.
pre-mRNA 3'-splice site binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| U2AF1 | Myelodysplastic syndromes, AML | Knock-in of mutant U2AF1 in hematopoietic cells |
| STMN2 | ALS, TDP-43 proteinopathy | CRISPR knockout of TDP-43 in neurons |
| ABCA4 | Stargardt disease | Minigene splicing assays with patient variants |
| FUBP1 | Cancer, splicing regulation | Knockout in cancer cell lines |
| TDP-43 | ALS, FTD | Overexpression or knockout in neuronal models |
Cancer
Recurrent mutations in U2AF1, a core component of the 3' splice site recognition machinery, are found in myelodysplastic syndromes and acute myeloid leukemia. These mutations alter 3' splice site preference and promote oncogenic splicing programs. Similarly, mutations in other spliceosome genes such as SRSF2 and SF3B1 affect 3' splice site selection and contribute to cancer pathogenesis. Targeting the 3' splice site binding machinery is therefore a potential therapeutic strategy in splicing-mutant cancers.
Neurodegeneration
In amyotrophic lateral sclerosis (ALS) and frontotemporal dementia, loss of nuclear TDP-43 leads to cryptic 3' splice site usage in STMN2, resulting in a truncated protein and axonal degeneration. Antisense oligonucleotides that block the cryptic 3' splice site restore STMN2 function, demonstrating the therapeutic potential of targeting 3' splice site recognition. This example highlights how dysregulation of GO:0030628 contributes to neurodegeneration.
Inherited retinal disease
Stargardt disease is caused by mutations in ABCA4, many of which are noncanonical splice site variants that affect 3' splice site recognition. Minigene assays have revealed the full spectrum of splicing defects caused by these variants, providing a basis for genetic diagnosis and potential splice-modulating therapies.
From pre-mRNA 3'-splice site binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene regulate 3' splice site binding? | CRISPR knockout cell line |
| Does a specific mutation alter 3' splice site recognition? | Point-mutation knock-in via CRISPR |
| Can a disease variant be corrected? | Knock-in of wild-type or mutant minigene |
| Where does a factor bind on pre-mRNA? | Tagged knock-in for CLIP-seq |
| Does overexpression of a splicing factor affect splicing? | Overexpression cell model |
| Can cryptic 3' splice site usage be modulated? | Antisense oligonucleotide treatment in knockout cells |
How to Study the pre-mRNA 3'-splice site binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Minigene assay | Splicing of a test exon | Validation of splice site variants |
| RNA-seq | Genome-wide splicing changes | Knockout/knockdown studies |
| CLIP-seq | Protein-RNA binding sites | Mapping 3' splice site binding |
| CRISPR screen | Genes affecting splicing | Discovery of novel regulators |
| RT-PCR | Specific splice isoform levels | Quantification of splicing events |
| Antisense oligonucleotide | Blocking cryptic splice sites | Therapeutic correction |
| AI-assisted prediction | Variant impact on splicing | Clinical interpretation |
| Proteomics | Protein interactions | Spliceosome composition |
Minigene splicing assays
Minigene assays are used to test the impact of specific mutations on 3' splice site recognition. By cloning a genomic segment containing the splice site into a reporter vector and transfecting cells, researchers can quantify inclusion or skipping of the test exon using RT-PCR. This method is particularly useful for validating noncanonical splice site variants identified in patients.
RNA-seq and splicing analysis
RNA sequencing (RNA-seq) allows genome-wide assessment of splicing changes upon perturbation of 3' splice site binding factors. Differential splicing analysis can reveal cryptic 3' splice site activation, intron retention, and exon skipping events. When combined with CRISPR knockout of candidate factors, RNA-seq provides a powerful approach to define the regulon of a splicing factor.
CLIP-seq and related methods
Crosslinking and immunoprecipitation followed by sequencing (CLIP-seq) maps the RNA binding sites of proteins at nucleotide resolution. For 3' splice site binding factors such as U2AF2 or FUBP1, CLIP-seq can identify direct binding sites and reveal sequence preferences. This method is essential for understanding the specificity of GO:0030628.
CRISPR-based screens
Genome-wide CRISPR screens can identify genes that modulate 3' splice site recognition. For example, a reporter cell line with a fluorescent readout of splicing can be used to screen for modifiers. Such screens have the potential to uncover novel regulators of GO:0030628 and to link them to disease.
How CRISPR Can Be Used to Study GO:0030628 pre-mRNA 3'-splice site binding
Knockout
CRISPR knockout of genes encoding 3' splice site binding factors (e.g., U2AF1, FUBP1) allows researchers to assess their essentiality and to identify the splicing events they control. Knockout cell lines can be analyzed by RNA-seq to reveal global splicing defects. Conditional knockout models are useful for studying tissue-specific functions.
Point Mutation
Point mutations in 3' splice site sequences or in the genes encoding binding factors can be introduced using CRISPR base editing or homology-directed repair. Such models are valuable for dissecting the functional impact of disease-associated variants, such as those in ABCA4 or U2AF1.
Knock-in
Knock-in of reporter tags (e.g., GFP or HA) into endogenous loci enables visualization and immunoprecipitation of 3' splice site binding factors. Tagged knock-in models are particularly useful for CLIP-seq and live-cell imaging studies.
Overexpression
Overexpression of wild-type or mutant splicing factors can be achieved by CRISPR-mediated knock-in of a strong promoter or by lentiviral delivery. Overexpression models help determine whether increased levels of a factor alter 3' splice site selection and contribute to disease.
How EDITGENE Supports pre-mRNA 3'-splice site binding Research
Researchers studying pre-mRNA 3'-splice site binding-related genes often need to determine whether a candidate gene is causally involved in splicing regulation or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from knockout and point-mutation models to library screening and bioinformatics analysis.
Contact EDITGENE today to design your custom CRISPR model for pre-mRNA 3'-splice site binding research.
Frequently Asked Questions About pre-mRNA 3'-splice site binding
What is pre-mRNA 3'-splice site binding?
pre-mRNA 3'-splice site binding (GO:0030628) is the molecular function of selectively binding to the 3' splice site sequence of a pre-mRNA, a key step in spliceosome assembly.
What genes are involved in pre-mRNA 3'-splice site binding?
Key genes include U2AF1, U2AF2, FUBP1, and other splicing factors that recognize the 3' splice site.
How does U2AF recognize the 3' splice site?
U2AF2 binds the polypyrimidine tract, while U2AF1 contacts the AG dinucleotide at the 3' splice site, facilitating U2 snRNP recruitment.
What diseases are linked to 3' splice site mutations?
Mutations in 3' splice sites cause Stargardt disease, and mutations in U2AF1 are linked to myeloid cancers. Cryptic 3' splice site usage in STMN2 is associated with ALS.
How can I study pre-mRNA 3'-splice site binding?
Common methods include minigene assays, RNA-seq, CLIP-seq, and CRISPR knockout/knock-in models.
What is the role of FUBP1 in splicing?
FUBP1 facilitates 3' splice site recognition and splicing of long introns by promoting U2AF recruitment.
Can CRISPR be used to model 3' splice site mutations?
Yes, CRISPR point-mutation knock-in can introduce disease-associated variants into the genome to study their impact on splicing.
What is cryptic 3' splice site activation?
Cryptic 3' splice site activation occurs when a mutation or loss of a splicing factor causes the spliceosome to use a nearby alternative 3' splice site, leading to aberrant mRNA.
How does TDP-43 affect 3' splice site binding?
Loss of TDP-43 leads to cryptic 3' splice site usage in STMN2, which can be corrected by antisense oligonucleotides.
What services does EDITGENE offer for splicing research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services for studying pre-mRNA 3'-splice site binding.
Conclusion
pre-mRNA 3'-splice site binding (GO:0030628) is a fundamental molecular function that ensures accurate intron removal and gene expression. Its dysregulation is implicated in a wide range of human diseases, from cancer to neurodegeneration and inherited retinal disorders. Continued research using CRISPR models and advanced sequencing technologies will further illuminate the mechanisms and therapeutic potential of targeting 3' splice site recognition.
References
- 1. Baralle D et al.. 2005. Splicing in action: assessing disease causing sequence changes.. J Med Genet 42(10):737-48 PMID: 16199547
- 2. Baughn MW et al.. 2023. Mechanism of STMN2 cryptic splice-polyadenylation and its correction for TDP-43 proteinopathies.. Science 379(6637):1140-1149 PMID: 36927019
- 3. Martinez NM et al.. 2022. Pseudouridine synthases modify human pre-mRNA co-transcriptionally and affect pre-mRNA processing.. Mol Cell 82(3):645-659.e9 PMID: 35051350
- 4. Shao C et al.. 2025. Dynamic U2AF cycling defines two phases of cotranscriptional pre-mRNA splicing.. Science 389(6767):eadj9141 PMID: 40997183
- 5. Sangermano R et al.. 2018. ABCA4 midigenes reveal the full splice spectrum of all reported noncanonical splice site variants in Stargardt disease.. Genome Res 28(1):100-110 PMID: 29162642
- 7. Ebersberger S et al.. 2023. FUBP1 is a general splicing factor facilitating 3' splice site recognition and splicing of long introns.. Mol Cell 83(15):2653-2672.e15 PMID: 37506698
- 8. Guerra-Moreno Á et al.. 2023. AI-assisted proofreading of RNA splicing.. Genes Dev 37(21-24):945-947 PMID: 38092520
